PSORIASIS

This study looks at the long-term safety and effectiveness of the drug deucravacitinib for people with moderate-to-severe plaque psoriasis. Participants had already been in earlier studies of this drug. The study also checks how well the drug works with certain vaccines. About 1,…

This study tracks the long-term safety of ustekinumab, a medication for moderate to severe plaque psoriasis, in children aged 6 to 17. Researchers monitor for serious infections, cancers, and autoimmune problems, as well as effects on growth and puberty. The goal is to ensure the…

This study tests whether adding a weight-loss drug (tirzepatide) to a standard psoriasis medication (ixekizumab) helps people with moderate-to-severe psoriasis and obesity or overweight lose weight while clearing their skin. About 250 adults will receive either ixekizumab alone o…

This study tests a drug called guselkumab in children and teens (ages 6 to 17) with chronic plaque psoriasis, a skin condition causing red, scaly patches. The goal is to see if the drug safely clears or reduces the skin plaques. About 120 participants will receive either guselkum…

This study tracks how well risankizumab works for adults recently diagnosed with moderate plaque psoriasis (within the last 2 years) who haven't tried advanced treatments before. About 250 people in Greece will receive the drug as prescribed by their doctor and be observed for up…

This study looks at the long-term safety and effectiveness of the drug ESK-001 in adults with moderate to severe plaque psoriasis. Participants must have completed a prior ESK-001 study. They will take ESK-001 twice daily for 24 weeks, then some may switch to a placebo to see if …

This early-stage study tests a new drug called CMAB015, which is similar to the approved psoriasis treatment Cosentyx. It involves 114 healthy Chinese men to see how the body processes the drug, its safety, and whether it triggers an immune response. The goal is to compare the ne…

This study tests whether a single injection of risankizumab (Skyrizi) can clear psoriasis for up to 66 weeks in some patients. Researchers will analyze skin biopsies to understand how the drug changes immune cells and why some people stay clear without ongoing treatment. The goal…

This study watches for side effects in 881 people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis who receive Remsima under the skin. It aims to see how safe the injection is over time. Participants must have active disease that didn't respond…

This study tests a single dose of brodalumab in children aged 6 to 17 with severe plaque psoriasis. The goal is to check safety and how the drug works in the body. Only 2 children are enrolled, so results are very early.

This study tests whether a dedicated care coordinator can help people with psoriasis or psoriatic arthritis lower their risk of heart disease. About 520 adults aged 40-75 who are not already on cholesterol medication will receive support to manage risk factors like high cholester…

This Canadian study follows about 400 adults with plaque psoriasis who are starting brodalumab as part of their routine care. Over 12 months, researchers measure changes in skin-related quality of life, work productivity, and treatment satisfaction. The goal is to understand how …

This study tests whether a daily pill called IRX4204 can safely improve skin symptoms in adults with mild to moderate plaque psoriasis. About 20 participants will take the drug or a placebo for 28 days and have weekly checkups. The goal is to see if the drug clears or nearly clea…

This study tests whether a TENS device, which sends mild electrical pulses through sticky pads on the skin, can reduce pain from biologic injections in people with psoriasis. About 20 adults will receive one injection without TENS and another with TENS, then rate their pain. The …

This early study tests a special microbubble bath (Thera-Clean) that uses no chemicals to clean skin, reduce itch, and help wounds heal. About 20 people aged 2 and older with epidermolysis bullosa, ichthyosis, atopic dermatitis, or psoriasis will use the bath at home for 8 weeks.…

This study is a large registry that will follow 10,000 adults with psoriasis to see how safe and effective current treatments are in everyday medical practice. Researchers will track side effects like infections, heart problems, and cancer, as well as how well the treatments cont…

This study is creating a large registry of up to 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants over time to see how treatments work in everyday medical practice and track any side effects. T…

This study tracks 3,500 adults with moderate-to-severe psoriasis to compare the long-term safety of the drug brodalumab against other psoriasis treatments. Participants are already taking or switching to a systemic therapy as part of their normal care. The main goal is to see how…

This study looks at how the drug tildrakizumab works in the skin of 3 adults with moderate to severe plaque psoriasis. Researchers will take small skin samples before and after treatment to see how immune cells change. The goal is to understand why the drug works well for some pe…

This study aims to find which people with psoriasis are more likely to develop insulin resistance, a condition that can lead to diabetes and heart disease. Researchers will analyze medical records from over 1,200 patients to build a simple, understandable tool that doctors can us…

This study looks at whether a reporting system helps psoriasis patients take their medication (deucravacitinib) as prescribed. Forty adults with moderate-to-severe psoriasis will be split into two groups: one uses a reporting tool, the other does not. Researchers will interview p…

This study is a large registry that follows over 15,000 people with psoriasis to monitor the long-term safety of various treatments, including biologic drugs like infliximab, ustekinumab, and guselkumab. Participants receive their usual care while researchers track side effects, …

This early-stage study is testing a single dose of a new drug called SHR-1139 in 24 healthy adults. The main goal is to see if it is safe and how the body processes it. This is a first step toward possibly treating psoriasis, but no patients with the condition are involved yet.

This study aimed to understand why psoriasis and lichen planus often develop where skin is rubbed or pressed, like under tight clothing. Researchers planned to irritate a small area of skin with tape or a spatula, then take samples to study the inflammation. The study was withdra…

This study looks at whether a combination of a medicated foam (Enstilar®) and narrow-band UVB light can change the 'memory' of psoriasis skin. Psoriasis often returns even after skin looks healed, possibly because certain immune cells (TRM cells) remember the disease. The study i…